W-Series capsule
Varda Space Industries · United States · Space · also known as Varda W-Series, W-1, W-2, W-3, W-4, W-5, W-6 · Updated
The W-Series capsule is an autonomous, free-flying orbital platform developed by Varda Space Industries of the United States, built to process small-molecule pharmaceutical crystals in microgravity and return them to Earth by parachute. One W-Series capsule, rather than a single fixed vehicle, covers a succession of missions numbered W-1 through W-6 so far, each launched as a rideshare payload.
Overview
Varda's business model is to grow pharmaceutical compounds in microgravity, where crystals can form with fewer defects than on Earth, then bring the processed material home for analysis. Each W-Series mission combines a satellite bus that holds the capsule in orbit, a processing module, and the reentry capsule itself. W-1, the first mission, launched in June 2023 on SpaceX's Transporter-8 rideshare and grew crystals of the antiretroviral drug ritonavir; after an initial reentry request was denied, it became the first commercial spacecraft to land on a US military test range when it came down at the Utah Test and Training Range in February 2024.
Since then, Varda has flown W-2 through W-6 on successive SpaceX Transporter rideshare missions, with most recent landings at the Koonibba Test Range in South Australia, operated by Southern Launch. Starting with W-4, Varda has built the capsule, processing hardware, heat shield and satellite bus itself, and W-4 was the first mission to fly under the company's own FAA Part 450 special vehicle operator licence.
Design and capabilities
Each capsule reenters the atmosphere at roughly orbital speed, about 8 km/s, shielded by a C-PICA (Conformal Phenolic Impregnated Carbon Ablator) heat shield that Varda manufactures at its El Segundo, California headquarters; the material was originally developed at NASA's Ames Research Center. After the hottest phase of reentry the capsule slows under a parachute to a land landing. Varda has not published the capsule's dimensions, mass or payload capacity.
Later missions have carried additional government-funded research instruments alongside the pharmaceutical payload. W-5, launched in November 2025, carried a US Navy reentry data-collection payload and flew Varda's next-generation satellite bus for the first time, reentering in January 2026. W-6, launched in March 2026 in partnership with the Air Force Research Laboratory, carried an autonomous star-and-satellite navigation experiment from Rhea Space Activity, advanced thermal-protection material samples from Sandia National Laboratories, and NASA-made heat-shield tiles, reentering in May 2026.
Use cases
Varda markets the W-Series primarily to pharmaceutical companies seeking microgravity crystallisation of drug compounds, and secondarily to government agencies as a reentry and hypersonic-testing platform. Varda itself operates every mission; it has not disclosed a per-mission or per-unit price for either use case.
Frequently asked questions
How many W-Series capsules have flown?
Six missions, W-1 through W-6, had launched as of the most recent public updates, beginning with W-1 in June 2023.
What does the W-Series capsule do?
It grows pharmaceutical crystals in microgravity aboard an orbiting satellite bus, then separates and reenters to deliver the processed material to a landing site on Earth.
How does the capsule survive reentry?
It reenters at roughly orbital speed behind a C-PICA heat shield developed from NASA Ames technology, then descends under a parachute to a land landing.
Where do the capsules land?
Early missions landed at the Utah Test and Training Range in the United States; more recent missions have landed at the Koonibba Test Range in South Australia.
Does the W-Series carry people?
No. It is an uncrewed cargo and research platform.
Who operates the W-Series?
Varda Space Industries operates every mission itself, flying pharmaceutical and government research payloads for customers.
